Navigation Links
Pharmos Issues Letter to Shareholders
Date:9/10/2007

in March 2007 after nearly 20 years of dedicated service to the Company. We wish him all the best in his retirement. Dr. Aviv remains a director of the Board of Pharmos.

As management, we are aware that at the time of this writing, our stock price is disappointingly low and not reflective of the underlying value in our assets. As fellow shareholders, we will do our utmost to unlock the value in the Pharmos pipeline by delivering meaningful clinical data, leveraging our R&D expertise and communicating this with the investment community.

With the changes put into place over the past year, we feel confidently that Pharmos has been fundamentally repositioned for growth and creating shareholder value, and we are excited to be with you on this journey. We thank our employees, partners and shareholders for your continued support and loyalty. We look forward to the year ahead, which we expect will be one of rebuilding through further developments and innovations in our clinical and preclinical programs.

Elkan R. Gamzu Alan L. Rubino

Chief Executive Officer President & Chief Operating Officer

--End of Letter to Shareholders --

About Pharmos Corporation

Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on pain/inflammation and autoimmune disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with irritable bowel syndrome (IBS). Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated. A second program in Phase 2a involves a clinical trial of our NanoEmulsion cream drug delivery system to deliver the NSAID diclofenac topic
'/>"/>

SOURCE Pharmos Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
2. Genomic DNA Preparation from RNAlater Preserved Tissues
3. Preparation of PCR Quality Template DNA from a Wide Range of Tissues Using InstaGene Matrix
4. Using the VersaFluor Fluorometer to Quantitate GUS Expression in Plant Tissues Bombarded With the Biolistic PDS-1000/He System
5. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
6. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
7. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
8. Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA)
9. Inline intellectual property raises legal issues
10. SC Johnson issues trademark warning over web offer
11. Company issues warning on outsourced software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Spartan Bioscience today announced that Paul ... by the Ottawa Chamber of Commerce as one of ... selected from over 240 applicants based on his business ... Spartan, Dr. Lem founded Plexagen Diagnostics, and also served ... a Medical Degree from the University of Ottawa, and ...
(Date:4/27/2015)... , April 27, 2015  For about a ... is their ability to utilize and catabolize glucose ... cancer cells is called the ,Warburg phenomenon", that ... of high oxygen presence, leading to enhanced lactate ... cells still choose glucose fermentation. A variety of ...
(Date:4/27/2015)... Diego, Calif. (PRWEB) April 27, 2015 ... of drug and chemical toxicity carries implications for advancing ... speaker April 28 at National University , the ... and presentation by Dr. Hanzlik, a professor at the ... drug metabolism and drug design, starts at 5 p.m. ...
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... in a line of reports paints a bleak picture ... such financing could be at its lowest level in ... to year's end. , ,The Money Tree Survey ... and the National Venture Capital Association, indicates that, unless ...
... Chippewa Valley representatives hope to score points with medical ... the largest medical device tradeshow in the Midwest. ... Minneapolis Convention Center on November 2nd and 3rd is ... company executives. , ,The twelve representatives include economic development ...
... Madison, Wis. - Sonic Foundry Inc. announced today ... "E-rate" program, which offers schools around the country the ... , ,The E-rate program is designed to provide discounts ... for the cost of education technology. Funded technology includes ...
Cached Biology Technology:While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 2While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 3While some bemoan lack of venture capital, entrepreneur touts `bootstrapping' for cash 4Chippewa Valley reps hope to score at Twin Cities tradeshow 2
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... determined that milk thistle extract, a widely used ... on the course of patients with alcoholic liver ... These findings are published in The American ... studies, milk thistle extracts have been shown to ...
... more than half of children with sore throat, exceeding ... antibiotics for 27 percent of children who received an ... 9 issue of JAMA. , Pharyngitis (inflammation of the ... to family medicine physicians and pediatricians, according to background ...
... young scientists in the University of York's Department of ... patients some of the unpleasant and dangerous side-effects of ... together with post-doctoral research fellow Mark Godber, have developed ... tumours more efficiently. , Now, the group has secured ...
Cached Biology News:Children overprescribed antibiotics for sore throat 2Young scientists turn to gel to ease side-effects of cancer treatment 2
TUNEL Apoptosis Detection Kit...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
HiTrap NHS-activated HP, 1 x 5 ml. Category: Chromatography Systems & Accessories, Systems....
Mouse Axl MAb (Clone 175128)...
Biology Products: